The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia


Cite item

Full Text

Abstract

The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of the tumor and have chosen patients, depending on the location of metastases and with proven maximum efficacy of eribulin. We have shown the side reactions and the possibility of application of eribulin in combination with other antineoplastic agents.

About the authors

L V Bolotina

P.A.Herzen Moscow Research Institute of Oncology of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Email: lbolotina@yandex.ru
д-р мед. наук, зав. отд-нием химиотерапии ФГБУ МНИОИ им. П.А.Герцена ФГБУ НМИРЦ 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 3

L V Manziuk

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. отд-нием изучения новых противоопухолевых препаратов ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V A Gorbunova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. отд-нием химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

E I Kovalenko

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

канд. мед. наук, науч. сотр. отд-ния изучения новых противоопухолевых препаратов ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

G Z Mukhametshina

Tatarstan Regional Clinical Cancer Center

канд. мед. наук, зав. отд-нием химиотерапии №1 ГАУЗ РКОД 420029, Russian Federation, Kazan, ul. Sibirskii trakt, d. 29

A I Khasanova

Tatarstan Regional Clinical Cancer Center

канд. мед. наук, зав. дневным стационаром №1 ГАУЗ РКОД 420029, Russian Federation, Kazan, ul. Sibirskii trakt, d. 29

L Yu Vladimirova

Rostov Research Institute of Oncology

д-р мед. наук, проф., зав. отд-нием противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

I S Mitashok

Rostov Research Institute of Oncology

зав. отд-нием противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

E P Prokofyeva

SFHI Penza Regional Oncology Dispensary

зав. отд-нием химиотерапии дневного стационара ГБУЗ ООД 440002, Russian Federation, Penza, pr-t Stroiteley, d. 37A

I V Evstigneeva

Tver Regional Clinical Oncology Dispensary

зав. диспансерным отд-нием ГБУЗ ТО ТОКОД 170008, Russian Federation, Tver, ul. 15 let Oktiabria, d. 57/37

I I Andreyashkina

Saratov Regional Oncology Dispensary No.2

канд. мед. наук, зав. отд-нием химиотерапии ГУЗ ООД №2 410053, Russian Federation, Saratov, Smirnovskoe ushhelye, d. 1

N A Abramova

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

I L Popova

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

E V Karabina

Tula Regional Oncology Dispensary

зав. химиотерапевтическим отд-нием ГУЗ ТООД 300040, Russian Federation, Tula, ul. Plehanova, d. 201a

A A Teterich

Belgorod Regional Oncology Dispensary

зав. дневным стационаром ОГБУЗ БОД 308010, Russian Federation, Belgorod, ul. Kuibysheva, d. 1

E A Gaysina

State Autonomous institution of public Health «Multidisciplinary Clinical Medical Center «Medical Town»

зам. глав. врача по терапии ГАУЗ ТО МКМЦ Медицинский город 625041, Russian Federation, Tiumen, ul. Barnaul'skaia, d. 32

V A Chubenko

SFHI St. Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Oncologic)

канд. мед. наук, зав. отд-нием химиотерапии ГБУЗ СПб КНпЦСВМП(о) 197758, Russian Federation, St. Petersburg, pos. Pesochnyj, Leningradskaja ul., d. 68A

S V Limareva

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

канд. мед. наук, науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

N M Tikhanovskaya

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

A E Storozhakova

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

N Yu Samaneva

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

Ya V Svetitskaya

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

T A Snezhko

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

E A Kalabanova

Rostov Research Institute of Oncology

врач-химиотерапевт отд-ния №2 противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344000, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

References

  1. Инструкция по медицинскому применению препарата Халавен® (РУ ЛП-001782 от 28.07.2012, с изменениями от 28.07.2016).
  2. Towle M.J, Salvato K.A, Wels B.F et al. Eribulin induces irreversible mitotic blockade: implications of cell - based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71 (2): 496-505.
  3. Funahashi et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sciens 2014; 105 (10): 1334-42.
  4. Ueda S, Saeki T, Takeuchi H et al. In vivo imaging of eribulin - induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer 2016.
  5. Partridge A.H et al. Chemo - and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer. J Clin Oncol 2014; 32: 3307-29.
  6. Advanced Breast Cancer Third International Consensus Conference; 5-7 November 2015: Lisbon, Portugal.
  7. Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open - label randomised study. Lancet 2011; 377 (9769): 914-23.
  8. Kaufman P.A, Cortes J, Awada A et al. Phase III open - label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan. J Clin Oncol 2015; 33 (6): 594-601.
  9. Twelves C, Awada A, Cortes J et al. Subgroup Analyses from a Phase 3, Open - Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic Clin Res 2016: 10 77-84.
  10. Pivot X, Marmé F., Koenigsberg R et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016; 27: 1525-31.
  11. Fornier M.N. Approved agents for metastatic breast cancer. Semin Oncol 2011; 38 (Suppl. 2): S3-S10.
  12. Cortes J, Vahdat L, Blum J.L et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28 (25): 3922-8.
  13. Van Persijn van Meerten E.L, Gelderblom H, Bloem J.L. RECIST revised: implications for the radiologist. A review article on the modi ed RECIST guideline. Eur Radiol 2010; 20 (6): 1456-67.
  14. Blum J.L, Twelves C.J, Dutcus C et al. Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or MBC treated with eribulin mesylate: results from the Phase III EMBRACE study. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010; San Antonio, TX. USA. P6-13-01.
  15. Twelves C et al. Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open - label, phase 2 dose - confirmation study. Presented at SABCS 2014. Abstract. P3-13-04.
  16. Wilks S, Puhalla S, O'Shaughnessy J et al. Phase 2, multicenter, singlearm study of eribulin mesylate with trastuzumab as first Line therapy for locally recurrent or metastatic HER2positive breast cancer. Clin Breast Cancer 2014; 14: 405-12.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies